Results of the switch from intravitreal ranibizumab to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration: A 42-month retrospective real-world study.

Ertan, E; Efe, N; Sabaner, M C; Dogan, M

Ertan, E; Efe, N; Sabaner, M C; Dogan, M.

Affiliation

Ertan E; Department of Ophthalmology, Gaziosmanpasa Training Hospital, Istanbul, Turkey.
Efe N; Department of Ophthalmology, Afyon University of Health Sciences, Afyonkarahisar, Turkey.
Sabaner MC; Department of Ophthalmology, Bafra State Hospital, Samsun, Turkey.
Dogan M; Department of Ophthalmology, Afyon University of Health Sciences, Afyonkarahisar, Turkey.

Niger J Clin Pract ; 24(12): 1824-1827, 2021 Dec.

Article in En | MEDLINE | ID: mdl-34889791

Subject(s)

Macular Degeneration; Ranibizumab; Angiogenesis Inhibitors; Follow-Up Studies; Humans; Intravitreal Injections; Macular Degeneration/drug therapy; Ranibizumab/therapeutic use; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retrospective Studies; Treatment Outcome; Visual Acuity

Key words

Aflibercept; age-related macular degeneration; ranibizumab; switch

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Ranibizumab / Macular Degeneration Type of study: Observational_studies / Prognostic_studies Limits: Humans Language: En Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google